Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study

PRINCETON, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that a data analysis of its ongoing Phase 1 clinical study of ADXS-cHER2 in canine osteosarcoma indicates that the immunotherapy breaks peripheral tolerance to HER2/Neu and induces HER2-specific T cell responses in dogs. Additionally, the data suggest that immune responses induced by ADXS-cHER2 target micrometastases and prevent the development of metastatic disease in this spontaneous and clinically relevant model of human osteosarcoma.

This data analysis was performed as an extension of the Phase 1 canine osteosarcoma clinical trial being conducted at the University of Pennsylvania School of Veterinary Medicine. According to the data analysis 50% of the dogs vaccinated with ADXS-cHER2 generated immunological responses against HER2 within four months of treatment. Clear immunological responses were detected against the intracellular component (IC1) of HER2, the highest conserved component between human and canine HER2.

David J. Mauro, M.D., Ph.D., Executive Vice President, Chief Medical Officer of Advaxis, commented, "Though a relatively small sample, this recent data analysis is very compelling and provides evidence that suggests the mechanism of action of ADXS-cHER2 directly contributes to a T-cell specific immune response. This attribute of ADXS-cHER2 has been shown previously in mouse models but now we have direct evidence of the effect in a spontaneous model of human cancer. This finding is also significant as it adds to the potential of Advaxis's ADXS-cHER2 human osteosarcoma program, as well as additional future programs in other HER2 overexpressing cancers such as breast, gastric and esophageal."

Preliminary findings of the Phase 1 clinical trial in dogs with osteosarcoma were presented during the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum by principal investigator, Nicola Mason, B.Vet.Med, PhD. The data suggest that ADXS-cHER2 is safe and well tolerated at doses up to 3 x 109 CFU with no evidence of cardiac, hematological, or other systemic toxicities. The study determined that ADXS-cHER2 is able to delay or prevent metastatic disease and significantly prolong overall survival in dogs with osteosarcoma that had minimal residual disease following standard of care (amputation and follow-up chemotherapy). At this time two-thirds of the treated dogs are still alive and median survival has not been reached. Conversely, dogs undergoing standard of care that did not receive ADXS-cHER2 had a median survival time of 316 days.

Advaxis has granted exclusive worldwide rights to Aratana Therapeutics (Nasdaq: PETX ) to develop and commercialize ADXS-cHER2 for the treatment of osteosarcoma in dogs. ADXS-cHER2 has been granted orphan drug status for the treatment of human osteosarcoma by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor Keytruda® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Keytruda is a registered trademark of Merck & Co.

CONTACTS:

Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.452.9813 ext. 102
 
Media Contact:
Tiberend Strategic Advisors, Inc.
Amy S. Wheeler
awheeler@tiberend.com
646.362.5750
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 13

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

Delicious New Dips by Dean's Perfect for Every Snack Lovers

Updated Category News Views 536

Dean's Dip Launches Five Exciting New Flavors Dean's Dip, a well-loved name in the dairy dip sector, is thrilled to introduce its latest flavors, catering to snack aficionados everywhere. In addition to its classic offerings, the brand is now adding two delightful new dips — Creamy Dill and Jalapeño Popper. But that's not all! A fresh sub-line of dips, the Cantina...

Continue Reading
Bavarian Nordic Secures $63 Million for Vaccine Manufacturing

Updated Category News Views 102

Bavarian Nordic Secures New Contract with U.S. Government Bavarian Nordic A/S (Copenhagen: BAVA) has announced an important contract with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). This order, worth USD 63 million, will enhance the nation's stockpile of smallpox/mpox vaccines and pave the way for producing more freeze-dried doses...

Continue Reading
NewtekOne, Inc. Declares Impressive Quarterly Dividend Update

Updated Category News Views 158

NewtekOne, Inc. Announces Quarterly Dividend Declaration NewtekOne, Inc. (NASDAQ: NEWT) has recently made an exciting announcement for its shareholders. The Board of Directors has declared a quarterly cash dividend amounting to $0.19 per share, which is a testament to the company's ongoing commitment to enhancing shareholder value. As the company gears up for this...

Continue Reading
New Clean Freak Car Wash Location Welcomes Local Community

Updated Category News Views 516

Exciting New Location of Clean Freak Car Wash Clean Freak Car Wash, an innovative company supported by Circle K, is thrilled to announce the grand opening of its latest location. This highly anticipated launch is set to bring exceptional car wash services, designed to provide customers with a refreshing and satisfying experience. Commitment to Quality and Eco-Friendly...

Continue Reading
Bernie Sanders Calls for Action Against Wealth Inequality Surge

Updated Category News Views 200

Bernie Sanders Raises Concerns Over Wealth Disparity Sen. Bernie Sanders has openly criticized the increasing wealth inequality in the country, highlighting the significant gains of a select group of billionaires. His latest remarks reflect deep concern for the financial struggles faced by millions of Americans. Wealth of Billionaires on the Rise In a striking statement,...

Continue Reading